Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07883512). This is a study registration, not published results. Lead sponsor: Virginia Commonwealth University. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 10 participants (ESTIMATED). Conditions: Breast Cancer, Supportive Care in Cancer. Interventions: DRUG: Empagliflozin. Primary outcome measures: Evaluate the feasibility of investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy, including participant recruitment , Day 1 (Estimated enrollment period of 6 months); Evaluate the acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy, including medication adherence , 45 Days (+/- a week); Evaluate the acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy including medication adherence , 45 Days (+/- a week); Evaluate the safety of 10 mg/day empagliflozin by evaluating medication tolerance , Baseline, through 3-month follow-up (45 days following treatment initiation (+/-) one week); Evaluate the safety of 10 mg/day empagliflozin by evaluating medication safety and tolerance , Baseline, through 3-month follow-up (45 days following treatment initiation (+/-) one week). Brief summary: The primary objective of this pilot study is to evaluate the feasibility and acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy.